Product Information
PROGLYCEM 50 MG/ML ORAL SUSP is a brand product labeled by Teva Pharmaceuticals USA Inc., priced at $16.4826 per ML under NDC 00575620030. Its NADAC has been published 466 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50 mg/mL
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00575620030
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
DIAZOXIDEApproval Type
New Drug (NDA)
FDA Application
NDA017453FDA Approved
Before 1982
TE Code
AB
On Market Since
9/30/1990
Price Statistics
The NADAC for PROGLYCEM 50 MG/ML ORAL SUSP has been published 466 times since Nov 28, 2013, and over the history we have for it it has risen 136.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $16.4826 per ML |
|---|---|
| All-time high | $16.9362 (May 13, 2026) |
| All-time low | $6.9693 (Nov 28, 2013) |
| 52-week high | $16.9362 |
| 52-week low | $15.2953 |
| Median price | $10.2519 |
| Average price | $10.8463 |
| Largest weekly change | +27.9% (Jul 17, 2024) |
| Weeks tracked | 466 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 57% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of PROGLYCEM 50 MG/ML ORAL SUSP?
The current National Average Drug Acquisition Cost (NADAC) for PROGLYCEM 50 MG/ML ORAL SUSP, manufactured by Teva Pharmaceuticals USA Inc., is $16.4826 per ML (NDC 00575620030), effective Aug 19, 2026.
How has the price of PROGLYCEM 50 MG/ML ORAL SUSP changed over time?
Over the history we have for it, the NADAC for PROGLYCEM 50 MG/ML ORAL SUSP has risen 136.5%. It has been tracked across 466 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PROGLYCEM 50 MG/ML ORAL SUSP?
Since Nov 28, 2013, the NADAC for PROGLYCEM 50 MG/ML ORAL SUSP has ranged from a low of $6.9693 (Nov 28, 2013) to a high of $16.9362 (May 13, 2026), with a median of $10.2519 per ML.
Are there cheaper alternatives to PROGLYCEM 50 MG/ML ORAL SUSP?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DIAZOXIDE 50 MG/ML ORAL SUSP, is $7.1450 per ML — about 57% below PROGLYCEM 50 MG/ML ORAL SUSP.
Who manufactures PROGLYCEM 50 MG/ML ORAL SUSP?
PROGLYCEM 50 MG/ML ORAL SUSP (NDC 00575620030) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a brand product.